Mirum Pharmaceuticals, Inc.

NasdaqGM:MIRM Stock Report

Market Cap: US$1.2b

Mirum Pharmaceuticals Dividend

Dividend criteria checks 0/6

Mirum Pharmaceuticals does not have a record of paying a dividend.

Key information

n/a

Dividend yield

n/a

Payout ratio

Industry average yield2.9%
Next dividend pay daten/a
Ex dividend daten/a
Dividend per sharen/a
Earnings per share-US$3.47
Dividend yield forecast in 3Y0%

Recent dividend updates

No updates

Recent updates

Mirum Pharmaceuticals: After Phase 2 Miss, An iBAT Inhibitor On Deck To Drive Value

Apr 22

Mirum Pharmaceuticals: Advancing On Several Key Fronts

Mar 05

There's Reason For Concern Over Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) Price

Dec 26
There's Reason For Concern Over Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) Price

What Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) P/S Is Not Telling You

Jun 10
What Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) P/S Is Not Telling You

Industry Analysts Just Made A Captivating Upgrade To Their Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Revenue Forecasts

Apr 18
Industry Analysts Just Made A Captivating Upgrade To Their Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Revenue Forecasts

Mirum's liver disease drug Livmarli gets EMA committee nod for approval in EU

Oct 14

Mirum: Great Sales Start For Livmarli Paves The Way For Long-Term Growth

Aug 17

Mirum Pharmaceuticals announces $80M stock offering

Aug 09

Mirum Pharmaceuticals: Post-Approval Execution Looks Excellent

May 27

Is Mirum Pharmaceuticals (NASDAQ:MIRM) In A Good Position To Invest In Growth?

Apr 22
Is Mirum Pharmaceuticals (NASDAQ:MIRM) In A Good Position To Invest In Growth?

Mirum Pharmaceuticals Gets The 'Thumbs Up'

Dec 16

Need To Know: Analysts Just Made A Substantial Cut To Their Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Estimates

Nov 25
Need To Know: Analysts Just Made A Substantial Cut To Their Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Estimates

Mirum And Maralixibat In Pediatric Cholestasis: The Differentiation

Aug 24

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if MIRM's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MIRM's dividend payments have been increasing.


Dividend Yield vs Market

Mirum Pharmaceuticals Dividend Yield vs Market
How does MIRM dividend yield compare to the market?
SegmentDividend Yield
Company (MIRM)n/a
Market Bottom 25% (US)1.5%
Market Top 25% (US)4.7%
Industry Average (Biotechs)2.9%
Analyst forecast in 3 Years (MIRM)0%

Notable Dividend: Unable to evaluate MIRM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate MIRM's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate MIRM's payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as MIRM has not reported any payouts.


Discover strong dividend paying companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.